Skip to main content
SpringerLink
Log in

TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC

  • Review
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly used staging system for hepatocellular carcinoma (HCC) in Western countries. BCLC aims to categorize patients into five stages with different prognoses and to allocate treatment according to these stages based on the best possible contemporary evidence. Transarterial radioembolization (TARE) has recently entered at the left of the BCLC algorithm (i.e., BCLC 0-A), mainly because of negative phase III trials in BCLC C stage. TARE has shown a steady increase in nationwide studies over the past 20 years and has even been adopted in some tertiary centers as the primary HCC treatment across all BCLC stages. We aimed to review the history of TARE in HCC, starting from advanced HCC and gradually expanding to earlier stages at the left of the BCLC system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona clinic liver cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8(2):78–91.

    Article  CAS  PubMed  Google Scholar 

  2. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

    Article  Google Scholar 

  3. Matsumoto MM, Mouli S, Saxena P, Gabr A, Riaz A, Kulik L, et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with bclc algorithm: 321-patient analysis. Cardiovasc Intervent Radiol. 2021;44(7):1070–80.

    Article  PubMed  Google Scholar 

  4. Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1000-patient 15-year experience. Hepatology. 2018;68(4):1429–40.

    Article  PubMed  Google Scholar 

  5. Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona clinic liver cancer (BCLC) staging system. The 2022 update. J Hepatol 2021.

  6. Tohme S, Bou Samra P, Kaltenmeier C, Chidi AP, Varley PR, Tsung A. Radioembolization for hepatocellular carcinoma: a nationwide 10-year experience. J Vasc Interv Radiol. 2018;29(7):912-9.e2.

    Article  PubMed  Google Scholar 

  7. Cassinotto C, Nogue E, Morell M, Panaro F, Molinari N, Guiu B. Changing trends in hepatocellular carcinoma management: results from a nationwide database in the last decade. Eur J Cancer. 2021;146:48–55.

    Article  PubMed  Google Scholar 

  8. Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (y90 radiating microspheres). Ann Surg. 1965;162(2):267–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, et al. History and evolution of yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med. 2019;8(1):55.

    Article  CAS  PubMed Central  Google Scholar 

  10. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15(4):335–45.

    Article  PubMed  Google Scholar 

  11. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29(4):522–9.

    Article  PubMed  Google Scholar 

  12. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71–81.

    Article  PubMed  Google Scholar 

  13. Kim GH, Kim JH, Kim PH, Chu HH, Gwon DI, Ko HK. Emerging trends in the treatment of advanced hepatocellular carcinoma: a radiological perspective. Korean J Radiol. 2021;22:1822–1833.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–9.

    Article  CAS  PubMed  Google Scholar 

  15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  16. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58(1):73–80.

    Article  PubMed  Google Scholar 

  17. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.

    Article  CAS  PubMed  Google Scholar 

  18. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826–37.

    Article  CAS  PubMed  Google Scholar 

  19. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.

    Article  PubMed  Google Scholar 

  20. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.

    Article  CAS  PubMed  Google Scholar 

  21. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.

    Article  CAS  PubMed  Google Scholar 

  22. Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74.

    Article  CAS  PubMed  Google Scholar 

  23. Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313.

    Article  CAS  PubMed  Google Scholar 

  24. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  PubMed  Google Scholar 

  25. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–50.

    Article  PubMed  Google Scholar 

  26. Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int. 2017;37(1):101–10.

    Article  CAS  PubMed  Google Scholar 

  28. Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, et al. Development of a prognostic score to predict response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68(4):724–32.

    Article  PubMed  Google Scholar 

  29. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.

    Article  CAS  PubMed  Google Scholar 

  30. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

    Article  CAS  PubMed  Google Scholar 

  31. Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29.

    Article  PubMed  Google Scholar 

  32. Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of use of Y90 as a Bridge to liver resection and transplantation in hepatocellular carcinoma. J Gastrointest Surg. 2021;25:2690–9.

    Article  PubMed  Google Scholar 

  33. Cardarelli-Leite L, Chung J, Klass D, Marquez V, Chou F, Ho S, et al. Ablative Transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2020;43(3):411–22.

    Article  PubMed  Google Scholar 

  34. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358-65.e1.

    Article  PubMed  Google Scholar 

  35. Kolligs FT, Bilbao JI, Jakobs T, Iñarrairaegui M, Nagel JM, Rodriguez M, et al. Pilot randomized trial of selective internal radiation therapy versus chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715–21.

    Article  PubMed  Google Scholar 

  36. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-63.e2.

    Article  PubMed  Google Scholar 

  37. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–8.

    Article  CAS  PubMed  Google Scholar 

  38. Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med. 2018;15(3):299–310.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Titano J, Noor A, Kim E. Transarterial chemoembolization and radioembolization across Barcelona clinic liver cancer stages. Semin Intervent Radiol. 2017;34(2):109–15.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology. 2021;73(3):998–1010.

    Article  CAS  PubMed  Google Scholar 

  41. Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381–400.

    Article  CAS  PubMed  Google Scholar 

  42. Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21(7):947–56.

    Article  CAS  PubMed  Google Scholar 

  43. Garin E, Palard X, Rolland Y. Personalised dosimetry in radioembolisation for HCC: impact on clinical outcome and on trial design. Cancers (Basel). 2020;12(6):1557.

    Article  CAS  Google Scholar 

  44. Kafrouni M, Allimant C, Fourcade M, Vauclin S, Guiu B, Mariano-Goulart D, et al. Analysis of differences between (99m)Tc-MAA SPECT- and (90)Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy. EJNMMI Res. 2019;9(1):62.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.

    Article  CAS  PubMed  Google Scholar 

  46. Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.

    Article  CAS  PubMed  Google Scholar 

  47. Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(12):1662-70.e4.

    Article  PubMed  Google Scholar 

  48. Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, et al. Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2018;41(10):1557–65.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673–84.

    Article  PubMed  Google Scholar 

  50. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51(9):1377–85.

    Article  CAS  PubMed  Google Scholar 

  51. Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73.

    Article  PubMed  Google Scholar 

  52. Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192–201.

    Article  PubMed  Google Scholar 

  53. Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–8.

    Article  PubMed  Google Scholar 

  54. Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol. 2017;28(6):777-85.e1.

    Article  PubMed  Google Scholar 

  55. Biederman DM, Titano JJ, Korff RA, Fischman AM, Patel RS, Nowakowski FS, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30-7.e2.

    Article  PubMed  Google Scholar 

  56. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342–52.

    Article  CAS  PubMed  Google Scholar 

  57. Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580–3.

    Article  CAS  PubMed  Google Scholar 

  58. Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.

    Article  PubMed  Google Scholar 

  59. Gabr A, Ranganathan S, Mouli SK, Riaz A, Gates VL, Kulik L, et al. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020;72(6):1151–8.

    Article  CAS  PubMed  Google Scholar 

  60. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16(6):1587–96.

    Article  PubMed  Google Scholar 

  61. Bekki Y, Marti J, Toshima T, Lewis S, Kamath A, Argiriadi P, et al. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery. 2021;169(5):1044–51.

    Article  PubMed  Google Scholar 

  62. Guiu B. Portal vein embolization versus yttrium-90 radioembolization: the race is not always to the swif the dosimetry-driven tortoise might well win the day! J Vasc Interv Radiol. 2021;32(6):843–4.

    Article  PubMed  Google Scholar 

  63. Guiu B, Herrero A, Panaro F. Liver venous deprivation: A bright future for liver metastases-but what about hepatocellular carcinoma? Hepatobiliary Surg Nutr. 2021;10(2):270–2.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392–401.

    Article  CAS  PubMed  Google Scholar 

  66. Vouche M, Degrez T, Bouazza F, Delatte P, Galdon MG, Hendlisz A, et al. Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. World J Hepatol. 2017;9(36):1372–7.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Allimant C, Deshayes E, Kafrouni M, Santoro L, de Verbizier D, Fourcade M, et al. Hepatobiliary scintigraphy and glass (90)Y radioembolization with personalized dosimetry: dynamic changes in treated and nontreated liver. Diagnostics (Basel). 2021;11(6):931.

    Article  CAS  Google Scholar 

  68. Radosa CG, Radosa JC, Grosche-Schlee S, Zöphel K, Plodeck V, Kühn JP, et al. Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice. Cardiovasc Intervent Radiol. 2019;42(3):405–12.

    Article  PubMed  Google Scholar 

  69. Di Federico A, Rizzo A, Carloni R, De Giglio A, Bruno R, Ricci D, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs 2021:1-9.

Download references

Acknowledgements

The authors thank Sandrine Guinodeau for revising the English.

Funding

Not supported by any funding.

Author information

Author notes

  1. Boris Guiu and Etienne Garin have contributed equally to this work.

Authors and Affiliations

  1. Department of Radiology, St-Eloi University Hospital, 80 Avenue Augustin Fliche, 34295, Montpellier, France

    Boris Guiu & Carole Allimant

  2. Department of Nuclear Medicine, Centre de Lutte Contre le Cancer Eugène Marquis, 35000, Rennes, France

    Etienne Garin

  3. Department of Oncology, Centre de Lutte Contre le Cancer Eugène Marquis, 35000, Rennes, France

    Julien Edeline

  4. Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, IL, 60611, USA

    Riad Salem

Authors
  1. Boris Guiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Etienne Garin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carole Allimant
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julien Edeline
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Riad Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Guiu.

Ethics declarations

Conflict of interest

Boris Guiu is consultant to Boston Scientific. Etienne Garin is consultant to Boston Scientific and reports receiving a grant, personal fees, and non-financial support from Boston Scientific. Julien Edeline reports receiving a grant from Boston Scientific; personal fees from Boston Scientific, Bayer, Roche, Eisai, Merck Sharpe and Dohme, AstraZeneca, and Ipsen; grants and personal fees from Bristol Myers Squibb; and non-financial support from Amgen, outside the submitted work. Riad Salem is a consultant to Boston Scientific, Bard, Sirtex, Eisai, Astrazeneca, Cook, Siemens and Genentech.

Consent for Publication

For this type of study consent for publication is not required.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors

Informed Consent

For this type of study informed consent is not required

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guiu, B., Garin, E., Allimant, C. et al. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol 45, 1599–1607 (2022). https://doi.org/10.1007/s00270-022-03072-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-022-03072-8

Keywords

Search

Navigation